Next Phase Newsletter

A women-led venture capital firm is dedicated to women’s health and have invested in over 10 companies in this space. The firm is looking to invest in life science companies that address women’s health between Seed to Series A in Europe, the UK, and Israel, eventually scaling to the U.S as well. The firm is open to acting as a lead investor for smaller rounds, however they are currently co-investing especially as they start to invest in the U.S. 
 
The firm is open to any life science sector including therapeutics, diagnostics, medical devices, digital health, etc. in the clinical stage as long as the company addresses women’s health. This includes innovations that solely, disproportionately, and/or differently affect women, such as menopause, autoimmune diseases, and heart disease. The firm is open to anywhere from therapeutics and genomics to consumer products. The firm requires to see clinical data and efficacy in the technology. In terms of medical devices, the firm is open to all classes. The only exception that the firm does not invest in is pharmaceuticals. 
 
The firm does not have specific team requirements, however the firm will take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm with offices in US and China has an active investment and advisory arm. The firm invests in early-stage life science ventures, from Seed to Series B, with Series A and Series B being the firm’s sweet spot. Typical size of investment ranges from $1-2M in seed stage companies, and $3-5M in venture round companies. In addition, the firm supports entrepreneurs to expand to the Chinese market, and the firm has multiple offices in China and needed expertise to support the entrepreneur’s vision. Currently, the firm is most interested in companies based in USA, Israel, and Western Europe. 
 
The firm will consider therapeutics, medical devices, diagnostics, and life science tools. The firm is most interested in medical devices, and their interests include medtech and biotech combination products, novel methods of drug delivery, in vitro diagnostics (novel instruments and reagents), etc. The firm is interested in both 510K and PMA devices. Within therapeutics, the firm is more interested in clinical assets and typically do not look at pre-clinical companies unless the opportunity is compelling. Current main indication areas of interest for the firm are cardiovascular disease, oncology, and women’s health. 
 
The firm seeks to work with management teams who are passionate about their technology and dedicated to creating values for the larger community. Though the firm is able to support companies who are interested in entering the China market, having a China angle is not necessary for investment. The firm can act as either a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm with offices in US and India is actively seeking investment and partnership opportunities with therapeutics and medical device companies across the globe. Typical size of initial investment is around $5M, though the firm is capable of investing up to $10M and this is largely dependent on a case-by-case. The firm is capable of funding up to ~40% of the required amount for late stage clinical trials. The firm is also interested in-licensing partnerships and seek licensing and marketing rights on opportunities in which the firm can add significant value. 
 
Within therapeutics and medical devices, the firm is generally sector and indication agnostic. The firm is focused on later-stage opportunities with a low risk profile, usually companies in Phase IIb and beyond. However, the firm is very keen to speaking with earlier stage opportunities that demonstrate strong clinical data and high potential to enter the global market and building a long-term relationship with these groups. In terms of medical devices, the firm will invest in near market ready products. The firm generally does not invest in diagnostics or digital health. 
 
The firm seeks to invest in companies with experienced management teams with domain expertise, strong clinical data, and a clear exit strategy. The firm has an extensive professional network including fellow investors, high net worth individuals, clinical trial/regulatory affairs partners, etc. The firm takes a very active role in supporting their portfolio companies and provides mentorship and support on regulatory issues, market access, and effective clinical development strategies. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm focused exclusively on the life sciences industry is making seed and venture investments and usually seeks to be the first institutional capital in a company. Equity investments are the preferred capital structure; however convertible notes may be employed for seed investments. Initial investments may be as small as $1M (seed-stage companies) with up to $15M allocated over the life of the investment. The firm invests in US and Canada. 
 
The firm is focused on investments in therapeutics, medtech and diagnostics. The firm is agnostic in terms of subsector and indication and invests in early pre-clinical up unto Phase III therapeutic assets with the caveat being that the capital needs of the company fall within the fund’s criteria for investment size. As for devices and diagnostics stage of development, the firm invests in products in development and in clinical settings given the aforementioned capital constraints for therapeutics. For medtech, the firm has a preference for 510(k) regulatory pathways but will also evaluate devices with a PMA pathway. 
 
The firm has no strict criteria for management teams and will work with novice entrepreneurs, however those management teams with experience are favored. The firm looks to originate 2/3 of its investments in Canada and the rest in the United States, and typically seeks a board seat along with investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture fund of a pharmaceutical seeks to invest in technologies that are complementary to the parent company’s R&D activities. The firm seeks to invest $5-7M as initial investment, and can invest up to $20M over the company’s lifecycle. The firm will focus on investing in companies in US and Europe. 
 
The firm focuses on investing in therapeutics, platform technologies, and digital technologies. In therapeutics, the firm has a strong interest in cell/gene therapy, as well as platform technologies including any platforms that can find or develop drugs across multiple therapeutic areas. Within digital technologies, the firm primarily seeks applications that help with target identification and drug design, accelerating drug discovery and development. The firm does not invest in medical devices or diagnostics. In terms of stage of development, the firm focuses on pre-clinical and early clinical stage opportunities. 
 
The firm does not have specific company or management team requirements. The firm does not lead investments and does not require board representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A French venture capital firm that has an additional office in the USA is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities but focuses on USA and Europe-based companies. 

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic but tend to stray away from cardiovascular and CNS indications. 

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A premier Saudi investment firm boasts a diverse portfolio that spans multiple asset classes, including real assets and alternative investments. Over the past decade, the investment firm has evolved into one of the region’s most compelling success stories, driven by a steadfast commitment to delivering value, fostering partnerships, and catalyzing sustainable development. Their vision is to become a leading integrated solutions provider in cell and gene therapy in Saudi Arabia, establishing themselves as the first globally trusted partner in precision medicine within the Middle East. The firm focus on providing research, manufacturing, and a comprehensive range of services related to genomic medicine, targeting local, regional, and international markets. Check sizes vary and are flexible but on average range between USD $5-10M. The firm aims to act as a catalyst for developing this vital industry and emphasize the importance of the private sector in supporting emerging, innovative sectors. Their aspiration is to accelerate the delivery of groundbreaking innovations and ensure patient access to treatments for chronic and rare diseases in the region. The firm is committed to contributing to the localization of the biotechnology industry as part of the global system and building national expertise to achieve these ambitious goals. 

Within therapeutics, the firm is focused on cell and gene therapy in IND, Phase 1 and/or moving into Phase 2. There are several indications of interest, including orphan diseases, oncology, neurology, immunology, cardiovascular diseases, and diabetes. For Tech-Driven Biosciences, the firm is interested in AI-driven platforms for drug discovery and clinical development. 

The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the region through manufacturing and clinical development. A carve out or partnership in the region is necessary. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.